Mohammed Milhem is an Oncology physician affiliated with University of Iowa. OpenAlex indexes 504 publications with 53,312 citations (h-index 67); ClinicalTrials.gov lists 13 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
200 Hawkins Dr
Iowa City, IA 522421009
Telephone
319-356-2324Registry record last updated 10 Nov 2008.
Clinical trials
- 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
Sponsor: Mohammed Milhem
- Seleno-L Methionine (SLM)-Axitinib-Pembrolizumab
Sponsor: Mohammed Milhem
- Chlorpromazine and Standard of Care in Glioblastoma
Sponsor: Mohammed Milhem
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
- Merck Sharp & Dohme LLCProgram year20222 payments
- Merck Sharp & Dohme CorporationProgram year20212 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
38.1%Mitogen-activated protein kinase (MEK) inhibitors12.3%Mektovi100%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors10.9%Braftovi100%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
23.2%Serotonin-3 Receptor Antagonist10.1%Ondansetron Hcl100%Part D≥21 patientsCorticosteroid8.4%Prednisone100%Part D≥18 patients+ 1 more class in this area
Sensory organs
10.9%Corticosteroid10.9%Dexamethasone62%Hydrocortisone39%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine
2023 - Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
New England Journal of Medicine
2021
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Perlman, MD
University of Iowa
Lawrence Hunsicker, MD
University of Iowa
Michael Abramoff, MD, PhD
University of Iowa
William Coryell, MD
University of Iowa
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”